PATENT CLAIM ANALYSIS

Application Number: 16035300
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "136100"]

Abstract:
The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Claim (Index 11):
A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of transformed cells expressing at least one vector encoding a T cell receptor (TCR) on the cell surface,\n wherein the TCR comprises one of the following CDR3\u03b1 chain/CDR3\u03b2 chain pairs:\n a CDR3\u03b1 chain comprising at least 95% identity to the amino acid sequence of SEQ ID NO: 3 and a CDR3\u03b2 chain comprising at least 95% identity to the amino acid sequence of SEQ ID NO: 9; \n a CDR3\u03b1 chain comprising at least 95% identity to the amino acid sequence of SEQ ID NO: 15 and a CDR3\u03b2 chain comprising at least 95% identity to the amino acid sequence of SEQ ID NO: 21; or \n a CDR3\u03b1 chain comprising at least 95% identity to the amino acid sequence of SEQ ID NO: 27 and a CDR3\u03b2 chain comprising at least 95% identity to the amino acid sequence of SEQ ID NO: 33; \n wherein the cancer is selected from the group consisting of gastrointestinal cancer, gastric cancer, acute myeloid leukemia, bone cancer, brain cancer, breast cancer, chronic lymphocytic leukemia, colon cancer, esophageal cancer, cervical cancer, kidney cancer, liver cancer, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, and urinary bladder cancer.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.77966
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15677651', '15461020', '15460654', '16023731', '14763421']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.783451580928593
- 35 USC 102 Novelty (BERT): 0.6645223170334412
- Combined Prediction Score: 0.7715586545390779
- Mean Citation Score: 587.633812
- Max Citation Score: 923.05096
- Similarity Product: 611.6402321925926

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test